Syngene, an integrated research, development, and manufacturing services company, acquired Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma, for $86 million. The site will add 20,000 liters of installed biologics drug substance manufacturing capacity for Syngene. The site has the potential for future expansion up to a further 20,000 liters of biologics drug substance manufacturing capacity. It also includes a commercial scale, high speed, fill-finish unit. Th...